• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Impact of pre-transplant infection management on the outcome of living-donor liver transplantation in Egypt.移植前感染管理对埃及活体肝移植结局的影响。
Infect Drug Resist. 2019 Jul 24;12:2277-2282. doi: 10.2147/IDR.S208954. eCollection 2019.
2
Impact of bacterial infections prior to liver transplantation on post-transplant outcomes in patients with cirrhosis.肝移植前细菌感染对肝硬化患者移植后结局的影响。
JHEP Rep. 2023 Jun 7;5(9):100808. doi: 10.1016/j.jhepr.2023.100808. eCollection 2023 Sep.
3
Health-related quality of life in Egyptian patients after liver transplantation.埃及肝移植患者的健康相关生活质量。
Ann Hepatol. 2012 Nov-Dec;11(6):882-90.
4
Liver Transplantation for Hepatitis B in Early Adulthood: Analysis of the United Network for Organ Sharing Database.成年早期乙肝患者的肝移植:器官共享联合网络数据库分析
Transplant Proc. 2016 Dec;48(10):3362-3367. doi: 10.1016/j.transproceed.2016.08.044.
5
Clinical Impacts of Donor Types of Living vs. Deceased Donors: Predictors of One-Year Mortality in Patients with Liver Transplantation.活体供体与尸体供体的供体类型对肝移植患者的临床影响:肝移植患者一年死亡率的预测因素
J Korean Med Sci. 2017 Aug;32(8):1258-1262. doi: 10.3346/jkms.2017.32.8.1258.
6
[Old donors in liver transplantation for chronic hepatitis C].[慢性丙型肝炎肝移植中的老年供体]
Rev Esp Enferm Dig. 2007 Oct;99(10):581-7. doi: 10.4321/s1130-01082007001000004.
7
Live donor liver transplantation for acute liver failure: A single center experience.活体供肝肝移植治疗急性肝衰竭:单中心经验
Indian J Gastroenterol. 2018 Jan;37(1):25-30. doi: 10.1007/s12664-017-0812-y. Epub 2018 Feb 17.
8
Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C.丙型肝炎移植后供肝年龄增长与纤维化快速进展
Gut. 2002 Aug;51(2):248-52. doi: 10.1136/gut.51.2.248.
9
Cytomegalovirus infection in living donor liver transplant recipients significantly impacts the early post-transplant outcome: A single center experience.活体供肝移植受者的巨细胞病毒感染对移植后早期结局有显著影响:单中心经验
Transpl Infect Dis. 2018 Aug;20(4):e12905. doi: 10.1111/tid.12905. Epub 2018 May 24.
10
Bacterial infections post-living-donor liver transplantation in Egyptian hepatitis C virus-cirrhotic patients: A single-center study.埃及丙型肝炎病毒肝硬化患者活体肝移植术后的细菌感染:一项单中心研究。
World J Hepatol. 2017 Jul 18;9(20):896-904. doi: 10.4254/wjh.v9.i20.896.

引用本文的文献

1
Chinese clinical practice guidelines for pediatric split liver transplantation.《小儿劈离式肝移植中国临床实践指南》
Liver Res. 2024 Nov 22;8(4):207-217. doi: 10.1016/j.livres.2024.11.002. eCollection 2024 Dec.
2
The Role of Pretransplant Infections in Pediatric Receiving LDLT in Indonesia: A 7-y Retrospective Study.移植前感染在印度尼西亚接受活体肝移植儿童中的作用:一项7年回顾性研究。
Transplant Direct. 2023 Feb 24;9(3):e1458. doi: 10.1097/TXD.0000000000001458. eCollection 2023 Mar.

本文引用的文献

1
Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.索磷布韦、聚乙二醇干扰素和利巴韦林在埃及丙型肝炎病毒感染人群真实临床实践中的治疗应用
Infect Disord Drug Targets. 2019;19(2):179-184. doi: 10.2174/1871526518666180912121835.
2
Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village.索磷布韦联合达卡他韦治疗埃及患者队列中的慢性丙型肝炎4型感染:一项埃及村庄规模的实验。
Int J Hepatol. 2018 Mar 20;2018:9616234. doi: 10.1155/2018/9616234. eCollection 2018.
3
Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection.在埃及丙型肝炎病毒4型感染患者中,使用索磷布韦加达拉他韦联合或不联合利巴韦林治疗的疗效及治疗反应预测因素。
Infect Drug Resist. 2018 Mar 28;11:441-445. doi: 10.2147/IDR.S160593. eCollection 2018.
4
Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection.索磷布韦-来迪帕司韦治疗一组埃及慢性丙型肝炎基因4型感染患者的疗效和安全性。
Infect Drug Resist. 2018 Mar 1;11:295-298. doi: 10.2147/IDR.S153060. eCollection 2018.
5
Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice.索磷布韦联合利巴韦林在真实临床实践中治疗基因4型丙型肝炎病毒肝硬化患者的疗效和安全性
Arch Virol. 2018 Jan;163(1):51-56. doi: 10.1007/s00705-017-3573-0. Epub 2017 Oct 5.
6
Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection.索磷布韦联合利巴韦林加或不加聚乙二醇干扰素-α治疗一组埃及丙型肝炎病毒感染患者的疗效
Infect Disord Drug Targets. 2017;17(2):95-100. doi: 10.2174/1871526517666170417143216.
7
Impact of preoperative infection on outcome after liver transplantation.术前感染对肝移植术后结局的影响。
Br J Surg. 2017 Jan;104(2):e172-e181. doi: 10.1002/bjs.10449.
8
Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX).成人肝移植适应症:奥地利胃肠病学和肝病学会(ÖGGH)与奥地利移植、输血和遗传学学会(ATX)合作提出的建议
Wien Klin Wochenschr. 2016 Oct;128(19-20):679-690. doi: 10.1007/s00508-016-1046-1. Epub 2016 Sep 2.
9
Pigtail Catheter: A Less Invasive Option for Pleural Drainage in Egyptian Patients with Recurrent Hepatic Hydrothorax.猪尾导管:埃及复发性肝性胸腔积液患者胸腔引流的一种侵入性较小的选择。
Gastroenterol Res Pract. 2016;2016:4013052. doi: 10.1155/2016/4013052. Epub 2016 Jun 2.
10
Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation.等待原位肝移植的肝硬化患者移植前评估中的感染相关考量
Curr Infect Dis Rep. 2016 Jan;18(2):4. doi: 10.1007/s11908-015-0514-5.

移植前感染管理对埃及活体肝移植结局的影响。

Impact of pre-transplant infection management on the outcome of living-donor liver transplantation in Egypt.

作者信息

Saleh Ahmed Mohamed, Hassan Essam Ali, Gomaa Ahmed Ali, El Baz Tamer Mahmoud, El-Abgeegy Mohamed, Seleem Mohamed Ismail, Abo-Amer Yousry Esam-Eldin, Elsergany Heba Fadl, Mahmoud Eman Ibrahim El-Desoki, Abd-Elsalam Sherief

机构信息

Tropical Medicine Department, Fayoum University, Al Fayyum, Egypt.

Endemic Medicine Department, Cairo University, Giza, Egypt.

出版信息

Infect Drug Resist. 2019 Jul 24;12:2277-2282. doi: 10.2147/IDR.S208954. eCollection 2019.

DOI:10.2147/IDR.S208954
PMID:31413604
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6661986/
Abstract

BACKGROUND AND AIM

Liver transplantation (LT) has emerged as an established therapeutic option for patients with chronic liver disease. Patients with end-stage liver disease are at high risk of infection with multidrug-resistant organisms, which may affect the outcome of LT. The aim of this study was to evaluate the impact of pre-transplant infection on the outcome of living-donor LT.

METHODS

Prospective follow-up was done for 50 patients with chronic liver disease who had had LT performed from September 2013 to December 2017. We divided patients into group 1 (patients who had had infection within 3 months before transplantation with adequate treatment [n=20]), and group 2 (patients without infection [n=30]). Both groups were followed for 4 months post-operatively.

RESULTS

Patients with high Model for End-Stage Liver Disease scores were more susceptible to infection pre- and post-operatively, and chest infection was the most common infection pre-transplant. There were no significant statistical differences regarding hospital and ICU stay and post-operative course between the groups, but the mortality rate was higher in group 1 (40%) than in group 2 (23.3%), and the causes of mortality in the group 1 were mainly due to medical causes (infections and sepsis, 75%) versus 28.6% in group 2.

CONCLUSION

Liver-cell failure and concomitant infection 3 months before LT with adequate treatment had no significant statistical differences regarding hospital, ICU stay, or medical complications, but post-operative infection and mortality rate were more frequent in group 1 and the causes of mortality were mainly medical.

摘要

背景与目的

肝移植(LT)已成为慢性肝病患者公认的治疗选择。终末期肝病患者感染多重耐药菌的风险很高,这可能会影响肝移植的结果。本研究的目的是评估移植前感染对活体肝移植结果的影响。

方法

对2013年9月至2017年12月期间接受肝移植的50例慢性肝病患者进行前瞻性随访。我们将患者分为第1组(移植前3个月内发生感染且治疗充分的患者[n = 20])和第2组(未发生感染的患者[n = 30])。两组患者均在术后随访4个月。

结果

终末期肝病模型评分高的患者在术前和术后更容易感染,移植前最常见的感染是肺部感染。两组患者在住院时间、重症监护病房(ICU)停留时间和术后病程方面无显著统计学差异,但第1组的死亡率(40%)高于第2组(23.3%),第1组的死亡原因主要是医疗原因(感染和脓毒症,75%),而第2组为28.6%。

结论

肝移植前3个月出现肝细胞衰竭并伴有感染且治疗充分,在住院时间、ICU停留时间或医疗并发症方面无显著统计学差异,但第1组术后感染和死亡率更高,且死亡原因主要是医疗原因。